Evaluation of Certain Drugs in Geriatric Patients

A Metaanalysis of Controlled Trials of Neuroleptic Treatment in Dementia

“…A total of 33 studies were identified in which neuroleptic medications were compared to placebo or to other medications in geriatric samples that comprised some dementia patients 12–44 . In studies intended to compare several medication classes in parallel groups, only neuroleptic and placebo data were used for the metaanalyses.…”

“…Studies Comparing Neuroleptics with Placebo Of the 17 placebo‐controlled studies identified, 12–28 13 used parallel groups and four used cross‐over designs. Eight of the 14 double‐blind studies used random treatment assignment, and one used “preassignment” to treatment (Table 1).…”

A Metaanalysis of Controlled Trials of Neuroleptic Treatment in Dementia

“…A total of 33 studies were identified in which neuroleptic medications were compared to placebo or to other medications in geriatric samples that comprised some dementia patients 12–44 . In studies intended to compare several medication classes in parallel groups, only neuroleptic and placebo data were used for the metaanalyses.…”

“…Studies Comparing Neuroleptics with Placebo Of the 17 placebo‐controlled studies identified, 12–28 13 used parallel groups and four used cross‐over designs. Eight of the 14 double‐blind studies used random treatment assignment, and one used “preassignment” to treatment (Table 1).…”

Neuroleptics in the treatment of dementia

“…Of the 18 items which make up this scale, the two areas which showed the greatest deterioration were motor activity and confusion. Interestingly, general sleep reports were improved on the Gottfries-Cronholm as well as the Crichton Scale (Robinson, 1959). Employing a somewhat higher dose of haloperidol (2.5 mg/day), Ter Haar (1977) showed a lack of improvement in a group of demented patients along measures of nightly unrest and activities of daily living.…”

Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia

“…However, another study (Auchus and BisseyBlack, 1997) found that 3 mg/d of haloperidol was no more effective than placebo in reducing agitation, but was associated with much greater toxicity. Likewise, one study has reported a slight improvement with chlorpromazine (Birkett and Boltuch, 1972), but several studies indicate a rate of deterioration that is similar to or higher than that seen among patients receiving placebo (Robinson, 1959;Birkett and Boltuch, 1972) Results with thioridazine have also been inconsistent. A six-week study (Phanjoo and Link, 1990) involving nine patients taking 50± 200 mg demonstrated a signi®cant reduction of patients' BPRS total scores from 24 to 7, although only one patient was rated as`very much improved' on the CGI-S. By contrast, an eight-week study (Barnes et al, 1982) found that thioridazine was no better than placebo on any item of the BPRS or on the Sandoz Clinical Assessment±Geriatric scale, but this may have been due to the use of a 25-mg/d dose, which may have been inadequate.…”

A Metaanalysis of Controlled Trials of Neuroleptic Treatment in Dementia

“…A total of 33 studies were identified in which neuroleptic medications were compared to placebo or to other medications in geriatric samples that comprised some dementia patients 12–44 . In studies intended to compare several medication classes in parallel groups, only neuroleptic and placebo data were used for the metaanalyses.…”

“…Studies Comparing Neuroleptics with Placebo Of the 17 placebo‐controlled studies identified, 12–28 13 used parallel groups and four used cross‐over designs. Eight of the 14 double‐blind studies used random treatment assignment, and one used “preassignment” to treatment (Table 1).…”

Neuroleptics in the treatment of dementia

“…Of the 18 items which make up this scale, the two areas which showed the greatest deterioration were motor activity and confusion. Interestingly, general sleep reports were improved on the Gottfries-Cronholm as well as the Crichton Scale (Robinson, 1959). Employing a somewhat higher dose of haloperidol (2.5 mg/day), Ter Haar (1977) showed a lack of improvement in a group of demented patients along measures of nightly unrest and activities of daily living.…”

Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia

“…However, another study (Auchus and BisseyBlack, 1997) found that 3 mg/d of haloperidol was no more effective than placebo in reducing agitation, but was associated with much greater toxicity. Likewise, one study has reported a slight improvement with chlorpromazine (Birkett and Boltuch, 1972), but several studies indicate a rate of deterioration that is similar to or higher than that seen among patients receiving placebo (Robinson, 1959;Birkett and Boltuch, 1972) Results with thioridazine have also been inconsistent. A six-week study (Phanjoo and Link, 1990) involving nine patients taking 50± 200 mg demonstrated a signi®cant reduction of patients' BPRS total scores from 24 to 7, although only one patient was rated as`very much improved' on the CGI-S. By contrast, an eight-week study (Barnes et al, 1982) found that thioridazine was no better than placebo on any item of the BPRS or on the Sandoz Clinical Assessment±Geriatric scale, but this may have been due to the use of a 25-mg/d dose, which may have been inadequate.…”

A Metaanalysis of Controlled Trials of Neuroleptic Treatment in Dementia

“…A total of 33 studies were identified in which neuroleptic medications were compared to placebo or to other medications in geriatric samples that comprised some dementia patients 12–44 . In studies intended to compare several medication classes in parallel groups, only neuroleptic and placebo data were used for the metaanalyses.…”

“…Studies Comparing Neuroleptics with Placebo Of the 17 placebo‐controlled studies identified, 12–28 13 used parallel groups and four used cross‐over designs. Eight of the 14 double‐blind studies used random treatment assignment, and one used “preassignment” to treatment (Table 1).…”

Neuroleptics in the treatment of dementia

“…Of the 18 items which make up this scale, the two areas which showed the greatest deterioration were motor activity and confusion. Interestingly, general sleep reports were improved on the Gottfries-Cronholm as well as the Crichton Scale (Robinson, 1959). Employing a somewhat higher dose of haloperidol (2.5 mg/day), Ter Haar (1977) showed a lack of improvement in a group of demented patients along measures of nightly unrest and activities of daily living.…”

Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia

“…However, another study (Auchus and BisseyBlack, 1997) found that 3 mg/d of haloperidol was no more effective than placebo in reducing agitation, but was associated with much greater toxicity. Likewise, one study has reported a slight improvement with chlorpromazine (Birkett and Boltuch, 1972), but several studies indicate a rate of deterioration that is similar to or higher than that seen among patients receiving placebo (Robinson, 1959;Birkett and Boltuch, 1972) Results with thioridazine have also been inconsistent. A six-week study (Phanjoo and Link, 1990) involving nine patients taking 50± 200 mg demonstrated a signi®cant reduction of patients' BPRS total scores from 24 to 7, although only one patient was rated as`very much improved' on the CGI-S. By contrast, an eight-week study (Barnes et al, 1982) found that thioridazine was no better than placebo on any item of the BPRS or on the Sandoz Clinical Assessment±Geriatric scale, but this may have been due to the use of a 25-mg/d dose, which may have been inadequate.…”